2,3-Dimethyl-5-phenylpyridin | 27068-59-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2,3-Dimethyl-5-phenylpyridin
• 英文别名: 5-phenyl-2,3-dimethylpyridine；2,3-dimethyl-5-phenyl-pyridine；2,3-Dimethyl-5-phenylpyridine；2,3-dimethyl-5-phenylpyridine
• CAS: 27068-59-3
• 化学式: C₁₃H₁₃N
• 分子量: 183.253
• InChiKey: NRKNBKIOSXIYRF-UHFFFAOYSA-N

物化性质

• 沸点：
  299.0±9.0 °C(Predicted)
• 密度：
  1.015±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-甲基-1-丁烯-3-酮 在 dipotassium peroxodisulfate 、 [Cp*CF₃RhCl₂]₂ 、 盐酸羟胺 、 silver(I) 4-methylbenzenesulfonate 、 sodium carbonate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 1.0h， 生成 2,3-Dimethyl-5-phenylpyridin
  参考文献：
  名称：

  Rh(III)-催化的丙烯酸与不饱和肟酯的脱羧偶联：羧酸用作无痕活化剂

  摘要：

  α,β-不饱和羧酸与α,β-不饱和O-新戊酰基肟进行Rh(III)催化的脱羧偶联，以良好的收率提供取代的吡啶。通过脱羧去除的羧酸作为无痕活化基团，产生具有非常高区域选择性的 5-取代吡啶。机理研究排除了吡啶甲酸中间体，可分离的铑配合物进一步阐明了反应机理。

  DOI：

  10.1021/ja412444d

文献信息

• Synthesis of Pyridines from Ketoximes and Terminal Alkynes via C–H Bond Functionalization
  作者：Rhia M. Martin、Robert G. Bergman、Jonathan A. Ellman

  DOI：10.1021/jo202280e

  日期：2012.3.2

  An expedient one-pot rhodium catalyzed C–H bond functionalization/electrocyclization/dehydration procedure has been developed for the synthesis of highly substituted pyridine derivatives from terminal alkynes and α,β-unsaturated ketoximes. The use of electron-deficient phosphite ligands is important to suppress dimerization of the terminal alkynes to enynes.

  已经开发了一种方便的一锅铑催化的 C-H 键官能化/电环化/脱水程序，用于从末端炔烃和 α,β-不饱和酮肟合成高度取代的吡啶衍生物。缺电子亚磷酸酯配体的使用对于抑制末端炔烃向烯炔烃的二聚化很重要。
• PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
  申请人：ARRAY BIOPHARMA INC.

  公开号：US20160297796A1

  公开（公告）日：2016-10-13

  Compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R 1 , R 2 , R a , R b , R c , R d , X, Ring B, and Ring C are as defined herein, and wherein Ring B moiety and the NH—C(═X)—NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.
• NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM
  申请人：Pimera, Inc.

  公开号：US20170334905A1

  公开（公告）日：2017-11-23

  Generally, the present invention provides novel quinolone compounds and pharmaceutical composition thereof which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing such compounds and compositions, and methods of making and using the same.
• US9828360B2
  申请人：——

  公开号：US9828360B2

  公开（公告）日：2017-11-28
• Rh(III)-Catalyzed Decarboxylative Coupling of Acrylic Acids with Unsaturated Oxime Esters: Carboxylic Acids Serve as Traceless Activators
  作者：Jamie M. Neely、Tomislav Rovis

  DOI：10.1021/ja412444d

  日期：2014.2.19

  α,β-Unsaturated carboxylic acids undergo Rh(III)-catalyzed decarboxylative coupling with α,β-unsaturated O-pivaloyl oximes to provide substituted pyridines in good yield. The carboxylic acid, which is removed by decarboxylation, serves as a traceless activating group, giving 5-substituted pyridines with very high levels of regioselectivity. Mechanistic studies rule out a picolinic acid intermediate

  α,β-不饱和羧酸与α,β-不饱和O-新戊酰基肟进行Rh(III)催化的脱羧偶联，以良好的收率提供取代的吡啶。通过脱羧去除的羧酸作为无痕活化基团，产生具有非常高区域选择性的 5-取代吡啶。机理研究排除了吡啶甲酸中间体，可分离的铑配合物进一步阐明了反应机理。